31 August 2018, Beijing. WHO and China have today signed a new funding agreement to support the response to the current Ebola virus outbreak in the Democratic Republic of the Congo (DRC), illustrating the strengthening of collaborative efforts between WHO and China towards the advancement of global public health.
More cities in China are following the trend and strengthening their smoke-free laws.
The World Health Organization urges Chinese citizens to continue to use quality-assured vaccines to prevent diseases in China. Immunization, while at the center of public debate in recent weeks, is one of the most effective, and cost-effective public health interventions in the world for preventing illness and death.
“Regulatory oversight of vaccines is critically important. It is the government's primary method of ensuring that the vaccines produced and used in China are safe, of good quality and effective,” said Gauden Galea, WHO Representative for China. “This incident shows that when regulatory oversight works well, potential risks can be averted.”
Highlights from the country
27 July 2018
In the context of China’s rapidly changing health landscape, the role of WHO in China continues to change as we work towards supporting ongoing reforms essential for safeguarding China’s transition to a more equitable, comprehensive and sustainable health system. This report captures some of the key highlights and achievements of WHO in China for the biennium 2016-2017 and the continued endeavour to add-value to China’s transformation and to its global health leadership in the future.
22 March 2016
On 22 March 2016, WHO Regional Director for the Western Pacific Dr Shin Young-soo and National Health and Family Planning Commission (NHFPC) Minister Li launched the new WHO-China Country Cooperation Strategy (CCS). The CCS outlines the priorities for WHO’s work in China over the next 5 years.
14 March 2016
In 2014 WHO recommended offering pre-exposure prophylaxis (PrEP) to men who have sex with men (MSM). On the basis of further evidence of the effectiveness and acceptability of PrEP, WHO has now broadened the recommendation to include all population groups at substantial risk of HIV infection.
Offering PrEP should be a priority for populations with an HIV incidence of about 3 per 100 person-years or higher. PrEP should be an additional prevention choice in a comprehensive package of services that also includes HIV testing, counselling, male and female condoms, lubricants, ARV treatment for partners with HIV infection, voluntary medical male circumcision and harm reduction interventions for people who use drugs.
14 March 2016
WHO Technical Consultation on a comprehensive National Hepatitis Programme in China with a focus on viral hepatitis B and C treatment, Beijing, China, 21 February 2014 : meeting report
China has a heavy burden of viral hepatitis. About 90 million people are chronically infected with the hepatitis B virus and about 7 to 10 million people are estimated to be infected with the hepatitis C virus. The consequence of chronic hepatitis is substantial - liver cancer is the second leading cause of death in China in the agegroup of 35-54 years of age. Effective treatment for hepatitis B and C is available. Studies show that treatment for hepatitis B and C is cost effective, and may reduce death due to chronic hepatitis-related liver disease including liver cancer.
In view of importance of chronic hepatitis in China, a technical consultation was held on 21 February 2014 in Beijing with national stakeholders to discuss the scientific evidence, current challenges and new opportunities for scaling up hepatitis treatment in China using the public health approach.